Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33863887.
- Also identified by DOI 10.1038/s41467-021-22580-8 and PMC identifier 8052374.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
Medical subject headings
- Antiviral Agents
- Cytidine
- Hydroxylamines
- SARS-CoV-2
- Virus Replication
- COVID-19 Drug Treatment